Leading with Extraordinary Clarity and Grace The LRA is enormously grateful to Mary K. (Peggy) Crow, MD for her more than 10 years of devoted service and leadership as the organization’s Co-Chair of our Scientific Advisory Board. Dr. Crow’s tenure concludes on December 31st. “It’s well known that Dr. Crow has brought vision … leadership […] READ MORE
BIG … BOLD … IDEAS ARE TRANSFORMING LUPUS RESEARCH—thanks to people like you! Thanks to our remarkable supporters, the Lupus Research Alliance awarded nearly $7.5 million through the following grant mechanisms in 2019: 2019 Novel Research Grants ($1,798,602) Carla Cuda, PhD The Role of Microglial Subsets in Driving Neuropsychiatric Symptoms of SLE Northwestern University – Chicago […] READ MORE
The Lupus Research Alliance (LRA) boldly pursued breakthroughs on the many fronts of lupus research in 2019—allowing the organization to fast-track avenues for new treatment options, including those orchestrated through our own clinical trials network. Throughout the year, the many brilliant scientists who received LRA funding brought new ideas to the table, ushering in discovery […] READ MORE
Taking a Closer Look at 2019 In the course of the year, the Lupus Research Alliance (LRA) took daring chances, pursued bold initiatives and made important strides in the conquest of lupus. With support from great friends, we: INVESTED IN TRAILBLAZING RESEARCH PUSHED THE LIMITS OF SCIENTIFIC DISCOVERY SOUGHT INNOVATIVE AVENUES OF INQUIRY The LRA […] READ MORE
December 10, 2019 The Lupus Research Alliance (LRA) is pleased to share that a potential new treatment in development by Equillium, Inc. for lupus nephritis, itolizumab, was granted Fast Track designation by the U.S. Food and Drug Administration. As defined by the FDA, this designation is “designed to facilitate the development, and expedite the review […] READ MORE
December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […] READ MORE
December 3, 2019 The Lupus Research Alliance (LRA) is pleased to share positive results reported by Biogen Inc. from the Phase 2 LILAC study which tested the effectiveness and safety of a potential lupus treatment, BIIB059. BIIB059 is a monoclonal antibody that targets BDCA2, a protein found on cells known as plasmacytoid dendritic cells, which […] READ MORE
November 26, 2019 – New York, NY – The Lupus Research Alliance (LRA) 2019 Breaking Through Gala gathered more than 600 members of the global lupus community last night to raise $3 million, all of which goes directly to lupus research. The theme, Breaking Through, celebrates the many research discoveries that LRA makes possible to […] READ MORE
Last week we gave you only half the story of what scientists funded by the Lupus Research Alliance (LRA) shared at 2019 ACR/ARP. So many studies were presented that we needed to bring you Part 2 to expand our coverage of the major discoveries your donations have made possible. And a Part 3 is yet […] READ MORE
November 14, 2019 The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly encouraged by the positive results reported for several potential new treatments that may help people with lupus. “The foundational work the Lupus Research Alliance and others have supported is beginning to bear fruit with potential […] READ MORE
November 12, 2019 The Lupus Research Alliance (LRA) is pleased to announce a new collaboration with the National Kidney Foundation (NKF) on a free course for healthcare professionals about ways to better diagnose, monitor and treat patients with systemic lupus erythematosus (SLE) and lupus nephritis. The online course is critically important because as the community […] READ MORE
November 14, 2019 The Lupus Research Alliance was proud of the unprecedented number of the studies supported by the Alliance chosen for presentation at the 2019 ACR/ARP Annual Meeting, the world’s largest rheumatology conference. A total of 19 studies were shared in oral presentations to large audiences, while 13 were presented as posters, which allow […] READ MORE
